favorite Patient and family resource

Understanding the m.3243A>G Mutation

You are not alone. This website is for individuals and families living with the m.3243A>G mitochondrial DNA change. You are not alone. This website is for individuals and families living with the m.3243A>G mitochondrial DNA change.

Whether you're newly diagnosed or supporting someone who is - we're here to help you understand what this means, one step at a time.

bolt I have MELAS hearing I have MIDD help I'm not sure
rocket_launch

Recently diagnosed?

Start with the most important first steps, without trying to learn everything at once.

arrow_forward groups

Find Community

Connect with patient organisations, online groups, and find specialist centres.

arrow_forward menu_book

Resources and tools

Find printable tools, clinical trials databases, and practical guides.

arrow_forward
genetics The Basics

What is the m.3243A>G Mutation?

A change in mitochondrial DNA that can affect how cells produce energy. A pathogenic MT-TL1 variant affecting mitochondrial translation and energy production. 12

Explanation
genetics

The Mutation

The name describes a change at position 3,243 in mitochondrial DNA: an A has changed to a G. It affects MT-TL1, a gene used to make a helper molecule called transfer RNA. m.3243A>G denotes an adenine-to-guanine substitution at mtDNA position 3243 in MT-TL1, which encodes mitochondrial tRNA-Leu(UUR). 12

bolt

Energy Production Can Be Affected

Mitochondria need these proteins to make energy efficiently. If protein production is disrupted, cells may struggle to meet their energy needs. The effect is not identical in every tissue. Impaired mitochondrial translation can compromise respiratory-chain function and oxidative phosphorylation. Biochemical expression varies with tissue, heteroplasmy and other factors. 123

account_tree

Many Possible Presentations

The same DNA change can produce different combinations of symptoms. Names such as MIDD and MELAS describe recognisable patterns, but they do not cover every person’s experience. m.3243A>G causes heterogeneous phenotypes, including syndromic, overlapping and non-syndromic presentations. 45

Gene MT-TL1
Inheritance Maternal
Prevalence Estimates vary
Common Labels MELAS, MIDD, CPEO+
Key Drivers Heteroplasmy + tissue mix
school Deep Dive: How the Mutation Works
rocket_launch Start Here

Recently Diagnosed?

It is okay to take this one step at a time. Follow any urgent instructions from your team; otherwise, these steps can help you prepare for your next appointment. It is okay to take this one step at a time. Follow any urgent instructions from your team; otherwise, these steps can help you prepare for your next appointment.

1

Review your medicines

Review medicines with your team using your exact diagnosis and health needs. Arrange genotype- and organ-specific medication review. 1617

Medication safety guide arrow_forward
2

Get an emergency letter

Carry a plan with your diagnosis, medicines and specialist contacts. Carry an individual emergency management plan and current medication list. 615

Wallet card arrow_forward Full letter arrow_forward
3

Set up monitoring

Agree a schedule for hearing, eyes, heart, kidneys and blood sugar checks. Individualise organ surveillance to phenotype and prior findings. 15

Monitoring schedule arrow_forward
4

Prepare for your next appointment

Your first appointments matter. Go in with the right questions and know what to expect.

Questions to ask arrow_forward Understanding your results arrow_forward
5

Tell your family

Discuss genetic counselling and whether maternal relatives should be offered testing. Discuss appropriate cascade counselling and testing in the maternal lineage. 1011

How to share arrow_forward
6

Look after yourself

Make room in your care plan for fatigue, emotional wellbeing and support. Assess fatigue, psychosocial burden and support needs alongside organ-specific care. 18

Self care guide arrow_forward
7

Connect with others

Patient organisations and support groups understand what you're going through.

Find support arrow_forward

Common Presentations

The same DNA change can produce different combinations of symptoms. Names such as MIDD and MELAS describe recognisable patterns, but they do not cover every person’s experience. m.3243A>G causes heterogeneous phenotypes, including syndromic, overlapping and non-syndromic presentations. 45

bolt

MELAS

Stroke-like episodes with variable effects on the brain and muscles Mitochondrial Encephalomyopathy, Lactic Acidosis & Stroke-like Episodes

MELAS includes stroke-like episodes and can also cause seizures, muscle problems, raised lactate and other organ problems. It can begin at different ages. MELAS is a clinical mitochondrial syndrome including stroke-like episodes, with variable encephalopathy, myopathy, hyperlactataemia and multisystem involvement. 26

Stroke-like episodes Acid buildup Lactic acidosis Seizures Migraines Muscle weakness Myopathy Hearing loss
Learn about MELAS arrow_forward
hearing

MIDD

Maternally Inherited Diabetes and Deafness

MIDD links inherited diabetes and hearing loss. It often appears in adulthood and can also affect other organs. MIDD commonly combines mitochondrial diabetes and sensorineural hearing loss, with possible retinal, cardiac, renal and neurological involvement. 7

Nerve-related hearing loss Sensorineural hearing loss Diabetes mellitus Retinal changes Macular retinopathy Heart muscle disease Cardiomyopathy Kidney disease Renal disease
Learn about MIDD arrow_forward
account_tree

Other Presentations

CPEO, overlap syndromes, isolated features, and mixed patterns

Other possible features include heart or kidney problems, digestive symptoms, drooping eyelids, limited eye movements, fatigue and muscle weakness. They do not all occur in everyone. Other manifestations include cardiomyopathy, nephropathy, gastrointestinal dysfunction, ptosis/ophthalmoplegia and myopathy. Expression varies considerably. 45

CPEO Overlap syndromes Isolated myopathy Hearing loss alone Asymptomatic carriers
Learn about the wider spectrum arrow_forward

Understanding Mutation Levels Heteroplasmy

A cell can contain both changed and unchanged copies of mitochondrial DNA. This mixture is called heteroplasmy, and its proportions can differ between organs and between people. Heteroplasmy is the coexistence of variant and reference mtDNA molecules. Variant fractions differ across tissues and individuals. 1258

Mutation level matters, but it is not a simple health score. A percentage from blood or urine does not show exactly what is happening in the brain, heart or muscles. Tissue heteroplasmy contributes to biochemical dysfunction, but peripheral measurements do not directly quantify every affected organ or determine phenotype. 58

Different people: similar measured percentages can accompany different symptoms. Phenotypic variability: similar heteroplasmy measurements do not imply equivalent disease burden. 58

science Tissue variation matters

A low or negative blood result may need further investigation if your history suggests mitochondrial disease. The genetics team may use urine or another sample and a sensitive test. A negative blood result does not exclude low-level m.3243A>G. Sample selection and assay sensitivity should match age, phenotype and clinical suspicion; urine may improve detection. 9

What mutation levels can tell you

MELAS - blood No defining range
MELAS - urine No defining range
MIDD - blood No defining range
MIDD - urine No defining range
No symptoms - blood Not a guarantee

There is no universal percentage at which someone develops diabetes, heart disease or MELAS. Tissue type, age and other biological factors also matter. Threshold effects depend on tissue and biological context. Fixed clinical thresholds cannot reliably classify MIDD, cardiac disease or MELAS. 58

school Learn more about heteroplasmy

Maternal Inheritance Pattern

Mitochondrial DNA is inherited through the mother. Maternal mtDNA transmission 1011

Mother with variant
Father (unaffected)
Daughter - at risk
Son - at risk

Children can inherit different mutation levels. A carrier daughter may pass the variant on; a carrier son is not expected to do so. Heteroplasmy can differ between offspring. Transmission through carrier women is possible; paternal transmission is not expected. 1011

Maternal Inheritance

Mitochondrial DNA is inherited through the mother. A woman who carries m.3243A>G may pass it to a child, but the amount inherited can vary. Men are not expected to pass this mitochondrial DNA change to their children. Pathogenic mtDNA variants follow maternal transmission. Heteroplasmic women can transmit variable variant loads; paternal transmission of m.3243A>G is not expected in clinical counselling. 1011

Siblings can inherit different mutation levels and have different health needs. A mother’s blood result cannot reliably predict a future child’s symptoms. Offspring heteroplasmy and phenotype can differ substantially within a family. Maternal blood heteroplasmy alone does not reliably predict fetal tissue load or clinical outcome. 1011

group Family testing matters

A diagnosis may be relevant to relatives on your mother’s side. A genetics team can map the family history and discuss who should be offered counselling and testing. Cascade counselling should follow the maternal pedigree; testing decisions consider relationship, age, consent and clinical context. 1011

person_search Find a genetic counsellor family_restroom Pregnancy guide

Who Should Consider Testing?

An unexplained combination of these features can be a reason to discuss a mitochondrial assessment. New neurological symptoms need urgent care. A suggestive multisystem or maternal pattern may warrant genetic assessment; acute neurological symptoms require urgent evaluation. 4579

hearing

Sensory clues

  • Hearing loss in both ears Bilateral sensorineural hearing loss 1213
  • Hearing loss together with diabetes Diabetes with sensorineural hearing loss 79
  • Unexplained changes at the centre of the retina Macular pattern dystrophy 1415
  • Drooping eyelids or limited eye movements Ptosis or external ophthalmoplegia 45
neurology

Neurological clues

  • Stroke-like episodes at any age Stroke-like episodes, including late onset 26
  • Headaches with other neurological features Migraine-like headache in a neurological presentation 26
  • Seizures without a clear explanation Unexplained epilepsy 26
  • Raised lactate needing interpretation Hyperlactataemia in clinical context 26
  • Episodes of confusion or changes in awareness Encephalopathic episodes 26
family_restroom

Family pattern clues

  • Diabetes among relatives on your mother’s side Maternal family history of diabetes 791011
  • Hearing loss among maternal relatives Maternal family history of hearing impairment 10111213
  • A confirmed m.3243A>G result in a maternal relative A confirmed m.3243A>G variant in the maternal pedigree 1011
  • Different organ problems in a maternal family pattern Multisystem disease with possible maternal transmission 451011
biotech Learn about the diagnostic tests

Explore

Every page aims to give you practical, reliable information in plain language.

bolt

MELAS Deep Dive

Stroke-like episodes, symptoms, emergency planning and the evidence for treatments. Stroke-like episodes, symptoms, emergency planning and the evidence for treatments.

hearing

MIDD Deep Dive

Hearing loss, diabetes, retinal involvement, and how MIDD is managed differently from other forms of diabetes.

 genetics

Understanding the Mutation

How the mutation works, heteroplasmy, and why symptoms vary so much - in plain language.

 biotech

Diagnosis Guide

Blood vs urine heteroplasmy, muscle biopsy, brain MRI, and the full diagnostic work-up.

 favorite

Daily Life

Medication review, supplement evidence, energy management and monitoring. Medication review, supplement evidence, energy management and monitoring.

menu_book

Resources

Patient organisations, support groups, clinical trial databases, OMIM, and specialist centres.

 groups

Community

Connect with patient organisations, online groups, and find specialist centres worldwide.

 chat

Feedback

Report a correction, suggest a resource, or subscribe to occasional updates about the site.

 info

About

Learn why this site exists, how it is researched, and how it is maintained.

References

18 sources

Sources for the information on this page.

  1. Goto Y, Nonaka I, Horai S. (1990). A mutation in the tRNA(Leu)(UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies. Nature. Research articleDOI↑ Back to text
  2. El-Hattab AW, Adesina AM, Jones J, Scaglia F. (2015). MELAS syndrome: Clinical manifestations, pathogenesis, and treatment options. Molecular genetics and metabolism. ReviewDOI↑ Back to text
  3. Suzuki T, Suzuki T, Wada T, Saigo K, Watanabe K. (2002). Taurine as a constituent of mitochondrial tRNAs: new insights into the functions of taurine and human mitochondrial diseases. The EMBO journal. Research articleDOIFull text↑ Back to text
  4. Nesbitt V, Pitceathly RD, Turnbull DM, Taylor RW, Sweeney MG, Mudanohwo EE, Rahman S, Hanna MG, McFarland R. (2013). The UK MRC Mitochondrial Disease Patient Cohort Study: clinical phenotypes associated with the m.3243A>G mutation--implications for diagnosis and management. Journal of neurology, neurosurgery, and psychiatry. Research articleDOI↑ Back to text
  5. Pickett SJ, Grady JP, Ng YS, Gorman GS, Schaefer AM, Wilson IJ, Cordell HJ, Turnbull DM, Taylor RW, McFarland R. (2018). Phenotypic heterogeneity in m.3243A>G mitochondrial disease: The role of nuclear factors. Annals of clinical and translational neurology. Research articleDOIFull text↑ Back to text
  6. Mancuso M, Bellusci M, Carelli V, de Coo I, Diodato D, Distelmaier F, Hikmat O, Hirano M, Horvath R, Karaa A, Klopstock T, Koenig MK, Kornblum C, La Morgia C, Lopriore P, Martikainen MH, McFarland R, Musumeci O, Pitceathly RDS, Primiano G, Rahman S, Scaglia F, Schaefer A, Schiff M, Semmler L, Lamperti C, Servidei S. (2026). Diagnostic Criteria and Management of MELAS and Stroke-Like Episodes: Consensus-Based Statements. European journal of neurology. Clinical guidanceDOIFull text↑ Back to text
  7. Chanoine JP, Thompson DM, Lehman A. (2025). Diabetes Associated With Maternally Inherited Diabetes and Deafness (MIDD): From Pathogenic Variant to Phenotype. Diabetes. ReviewDOIFull text↑ Back to text
  8. Grady JP, Pickett SJ, Ng YS, Alston CL, Blakely EL, Hardy SA, Feeney CL, Bright AA, Schaefer AM, Gorman GS, McNally RJ, Taylor RW, Turnbull DM, McFarland R. (2018). mtDNA heteroplasmy level and copy number indicate disease burden in m.3243A>G mitochondrial disease. EMBO molecular medicine. Research articleDOIFull text↑ Back to text
  9. Mavraki E, Labrum R, Sergeant K, Alston CL, Woodward C, Smith C, Knowles CVY, Patel Y, Hodsdon P, Baines JP, Blakely EL, Polke J, Taylor RW, Fratter C. (2023). Genetic testing for mitochondrial disease: the United Kingdom best practice guidelines. European journal of human genetics : EJHG. Clinical guidanceDOIFull text↑ Back to text
  10. Smeets HJM, Sallevelt SCEH, Herbert M. (2023). Reproductive options in mitochondrial disease. Handbook of clinical neurology. ReviewDOI↑ Back to text
  11. Castelluccio N, Spath K, Li D, De Coo IFM, Butterworth L, Wells D, Mertes H, Poulton J, Heindryckx B. (2025). Genetic and reproductive strategies to prevent mitochondrial diseases. Human reproduction update. ReviewDOI↑ Back to text
  12. Sue CM, Lipsett LJ, Crimmins DS, Tsang CS, Boyages SC, Presgrave CM, Gibson WP, Byrne E, Morris JG. (1998). Cochlear origin of hearing loss in MELAS syndrome. Annals of neurology. Observational studyDOI↑ Back to text
  13. Chinnery PF, Elliott C, Green GR, Rees A, Coulthard A, Turnbull DM, Griffiths TD. (2000). The spectrum of hearing loss due to mitochondrial DNA defects. Brain : a journal of neurology. Research articleDOI↑ Back to text
  14. Massin P, Virally-Monod M, Vialettes B, Paques M, Gin H, Porokhov B, Caillat-Zucman S, Froguel P, Paquis-Fluckinger V, Gaudric A, Guillausseau PJ. (1999). Prevalence of macular pattern dystrophy in maternally inherited diabetes and deafness. GEDIAM Group. Ophthalmology. Observational studyDOI↑ Back to text
  15. Sue CM, Balasubramaniam S, Bratkovic D, Bonifant C, Christodoulou J, Coman D, Crawley K, Edema-Hildebrand F, Ellaway C, Ghaoui R, Kava M, Kearns LS, Lee J, Liang C, Mackey DA, Murray S, Needham M, Rius R, Russell J, Smith NJC, Thyagarajan D, Wools C. (2022). Patient care standards for primary mitochondrial disease in Australia: an Australian adaptation of the Mitochondrial Medicine Society recommendations. Internal medicine journal. Clinical guidanceDOIFull text↑ Back to text
  16. De Vries MC, Brown DA, Allen ME, Bindoff L, Gorman GS, Karaa A, Keshavan N, Lamperti C, McFarland R, Ng YS, O'Callaghan M, Pitceathly RDS, Rahman S, Russel FGM, Varhaug KN, Schirris TJJ, Mancuso M. (2020). Safety of drug use in patients with a primary mitochondrial disease: An international Delphi-based consensus. Journal of inherited metabolic disease. Clinical guidanceDOIFull text↑ Back to text
  17. Mancuso M, Papadopoulou MT, Ng YS, Ardissone A, Bellusci M, Bertini E, Di Vito L, Evangelista T, Fons C, Hikmat O, Horvath R, Klopstock T, Kornblum C, Lamperti C, Licchetta L, Molnar MJ, Varhaug KN, O'Callaghan M, Pressler RM, Schiff M, Servidei S, Szabo N, Gorman GS, Cross JH, Rahman S. (2024). Management of seizures in patients with primary mitochondrial diseases: consensus statement from the InterERNs Mitochondrial Working Group. European journal of neurology. Clinical guidanceDOIFull text↑ Back to text
  18. Verhaak C, de Laat P, Koene S, Tibosch M, Rodenburg R, de Groot I, Knoop H, Janssen M, Smeitink J. (2016). Quality of life, fatigue and mental health in patients with the m.3243A > G mutation and its correlates with genetic characteristics and disease manifestation. Orphanet journal of rare diseases. Research articleDOIFull text↑ Back to text

Browse the research library for papers grouped by topic.

favorite Support